Astroglial cytoprotection by erythropoietin pre-conditioning: implications for ischemic and degenerative CNS disorders

J Neurochem. 2005 Apr;93(2):392-402. doi: 10.1111/j.1471-4159.2005.03038.x.

Abstract

Erythropoietin (Epo) is a glycoprotein secreted by the kidney in response to hypoxia that stimulates erythropoiesis through interaction with cell surface Epo receptors. Pre-treatment with Epo has been shown to protect neurons in models of ischemic injury. The mechanism responsible for this neuroprotection and the effects of Epo on astroglial and other non-neuronal cell populations remain unknown. In the present study, we determined whether Epo pre-treatment protects neonatal rat astrocytes from apoptotic cell death resulting from treatment with nitric oxide, staurosporine (STS) and arsenic trioxide and possible mechanisms mediating Epo-related cytoprotection. Epo (5-20 U/mL) significantly attenuated multiple hallmarks of apoptotic cell death in astroglia exposed to nitric oxide and STS but not arsenic trioxide. Epo (20 U/mL) induced mild oxidative stress as shown by increases in heme oxygenase (HO)-1 mRNA and protein expression that could be suppressed by antioxidant coadministration. Moreover, coincubation with tin-mesoporphyrin, a competitive inhibitor of HO activity, abrogated the cytoprotective effects of Epo (20 U/mL) in the face of STS treatment. Thus, induction of the ho-1 gene may contribute to the glioprotection accruing from high-dose Epo exposure. Epo may augment astroglial resistance to certain chemical stressors by oxidative stress-dependent and -independent mechanisms.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Apoptosis / physiology
  • Astrocytes / cytology
  • Astrocytes / drug effects*
  • Astrocytes / metabolism*
  • Cell Hypoxia / drug effects
  • Cell Hypoxia / physiology
  • Cells, Cultured
  • Central Nervous System Diseases / drug therapy*
  • Central Nervous System Diseases / metabolism
  • Central Nervous System Diseases / pathology*
  • Cytoprotection / drug effects*
  • Cytoprotection / physiology
  • Erythropoietin / pharmacology*
  • Erythropoietin / therapeutic use
  • Ischemic Preconditioning / methods
  • Neurodegenerative Diseases / drug therapy
  • Neurodegenerative Diseases / metabolism
  • Neurodegenerative Diseases / pathology
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Erythropoietin